Tandem Diabetes Care (TNDM) Equity Average (2014 - 2026)

Tandem Diabetes Care has reported Equity Average for 13 years, with the latest figure at $143.8 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 31.27% year-over-year to $143.8 million; the trailing twelve-month figure through Mar 2026 stood at $143.8 million (down 31.27% YoY), and the FY2025 full-year result was $209.1 million, down 27.48% from the prior year.
• Equity Average for Q1 2026 stood at $143.8 million, roughly flat from $144.1 million in the prior quarter.
• The five-year high for Equity Average was $443.5 million in Q2 2022, with the low at $133.1 million in Q3 2025.
• Historically, Equity Average has averaged $287.2 million across 5 years, with a median of $278.3 million in 2024.
• Annual changes were most pronounced in 2022 — Equity Average soared 34.49% — and 2025, when it slumped 43.54%.
• Tandem Diabetes Care's Equity Average stood at $430.9 million in 2022, then decreased by 27.17% to $313.8 million in 2023, then dropped by 20.21% to $250.4 million in 2024, then plunged by 42.47% to $144.1 million in 2025, then retreated by 0.2% to $143.8 million in 2026.
• The last three Equity Average figures came in at $143.8 million (Q1 2026), $144.1 million (Q4 2025), and $133.1 million (Q3 2025), per Business Quant data.